MedTrace Logo

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

NCT00952380 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-04-16

Study results available
· View outcomes & findings →

Summary

Three month treatment of acute VTE with Fragmin in pediatric cancer patients

Conditions

  • Venous Thromboembolism

Interventions

DRUG

dalteparin

dalteparin subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • United States
  • Norway
  • Russia
  • Slovenia
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00952380 on ClinicalTrials.gov